HUMA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 150907 min ago

@ $3.93

Išleistas: 14 vas. 2024 @ 16:30

Grąža: 90.59%

Ankstesnis signalas: vas. 13 - 19:18

Ankstesnis signalas: Pirkimas

Grąža: 2.88 %

Live Chart Being Loaded With Signals

Commentary (28 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	1.49M
Vidutinė apimtis	1.82M
Rinkos kapitalizacija	891.94M
EPS	$0 ( 2024-05-10 )
Kita pelno data	( $-0.230 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.49
ATR14	$0.0160 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Wallace Max N.	Buy	4 015	Common Stock
2024-05-20	Wallace Max N.	Buy	3 990	Common Stock
2024-05-20	Green Charles Bruce	Sell	600	Stock Options (right to buy)
2024-05-20	Green Charles Bruce	Buy	600	Common Stock
2024-05-17	Green Charles Bruce	Sell	600	Stock Options (right to buy)

INSIDER POWER
-72.58
Last 98 transactions
Buy: 5 300 522 \| Sell: 38 284 441

Tūris Koreliacija

Ilgas: 0.51 (weak)

Trumpas: 0.38 (neutral)

Signal:(49.027) Neutral

Humacyte, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Humacyte, Inc. Koreliacija - Valiuta/Žaliavos

-0.28
( neutral )

-0.38
( neutral )

0.00
( neutral )

0.07
( neutral )

-0.53
( weak negative )

0.76
( moderate )

Humacyte, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-7.72M (0.00 %)
EPS:	$-1.070

FY	2023
Pajamos:	$0
Bruto pelnas:	$-7.72M (0.00 %)
EPS:	$-1.070

FY	2022
Pajamos:	$1.57M
Bruto pelnas:	$-6.69M (-427.48 %)
EPS:	$0.620

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Humacyte, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.